Combination therapy using 9,3"-di-O-acetyl-midecamycin with beta-lactam antibiotics against Pseudomonas aeruginosa infection.
The combined effect of beta-lactam antibiotics and 9,3"-di-O-acetylmidecamycin were examined in 10 patients diagnosed as having chronic respiratory tract infections and complicated urinary tract infections. Patients were initially treated with 3 to 10 g/day of beta-lactams as intravenous infusions or by oral route for a certain period, after which period they were treated concurrently with 0.3 to 0.9 g/day of 9,3"-di-O-acetylmidecamycin by oral route. Through this combination therapy eradication of P. aeruginosa was obtained in 2 cases and remarkable decrease in another 2 cases out of the 10 cases. This combination therapy was judged to be effective in these 4 cases. Of the remaining cases, P. aeruginosa was eliminated before the start of the combination therapy in 3 cases, and no change in bacterial count was noted after the combination therapy in the other 3 cases.
D000328:Adult; D000361:Agammaglobulinemia / Q000150:complications; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D001987:Bronchiectasis / Q000188:drug therapy; D001991:Bronchitis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007933:Leucomycins / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015644:Miocamycin; D011552:Pseudomonas Infections / Q000188:drug therapy* / Q000382:microbiology; D011550:Pseudomonas aeruginosa / Q000276:immunology; D011656:Pulmonary Emphysema / Q000188:drug therapy; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy; D047090:beta-Lactams / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D047090:beta-Lactams; D015644:Miocamycin